SCHEMBL30729332

SCHEMBL30729332

CO/C=C1\COC2(CCN(C(=O)OCc3ccccc3)CC2)C1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
NPSR1 Q6W5P4 2/20 0.49
ALDH1A1 P00352 5/20 0.47
KDM4E B2RXH2 1/20 0.47
MAPT P10636 1/20 0.47
SMN1; SMN2 Q16637 4/20 0.46
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
CYP2C19 P33261 1/20 0.44
ALOX15 P16050 2/20 0.44
GAA P10253 1/20 0.44
HSD17B10 Q99714 1/20 0.44
SCN5A Q14524 1/20 0.43
SCN9A Q15858 1/20 0.43
HTT P42858 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
OPRD1 P41143 1/20 0.42
OPRK1 P41145 1/20 0.42
KDM1A O60341 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30720175 0.89 MEN1 (0.45) MEN1KMT2ANPSR1ALDH1A1KDM4E
SCHEMBL2845596 0.83 MEN1 (0.51) MEN1KMT2ANPSR1ALDH1A1KDM4E
SCHEMBL29319091 0.82 MEN1 (0.55) MEN1KMT2ANPSR1ALDH1A1KDM4E
SCHEMBL9572627 0.79 MEN1 (0.57) MEN1KMT2ANPSR1SMN1; SMN2NPC1
SCHEMBL541133 0.79 MEN1 (0.63) MEN1KMT2ANPSR1ALDH1A1KDM4E
SCHEMBL17572223 0.78 MEN1 (0.66) MEN1KMT2ANPSR1ALDH1A1KDM4E
SCHEMBL27194542 0.76 MEN1 (0.47) MEN1KMT2ANPSR1ALDH1A1SMN1; SMN2
SCHEMBL31311071 0.75 MEN1 (0.61) MEN1KMT2ANPSR1ALDH1A1KDM4E
SCHEMBL5406165 0.75 TMEM97 (0.52) MEN1KMT2ANPSR1ALDH1A1MAPT
SCHEMBL5406156 0.75 TMEM97 (0.52) MEN1KMT2ANPSR1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260028354-A1 TETRAHYDRONAPHTHALENE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS REGENT OF THE UNIV OF MICHIGAN (US) 2026-01-29 US disclosed
US-20260007681-A1 INDOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS UNIV MICHIGAN (US) 2026-01-08 US disclosed
EP-4554948-A1 TETRAHYDRONAPHTHALENE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS Regents of the University of Michigan (US) 2025-05-21 EP disclosed
WO-2024015406-A1 INDOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2024-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260028354-A1 TETRAHYDRONAPHTHALENE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS ESRRA, ESR2, ESRRB MEN1 3661/4885KMT2A 2018/4885NPSR1 75/4885
US-20260007681-A1 INDOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS ESRRA, ESR2, AR MEN1 3918/4885KMT2A 1708/4885NPSR1 25/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.